Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Core Viewpoint - Labcorp has launched a new blood-based biomarker test, the pTau-217/Beta Amyloid 42 Ratio, which aids in the diagnosis of Alzheimer's disease and meets performance criteria for confirming amyloid pathology consistent with the disease [1][2]. Group 1: Test Features and Benefits - The pTau-217/Beta Amyloid 42 Ratio test provides results comparable to positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, supporting neurologists and dementia specialists in diagnosing Alzheimer's disease [2]. - This test has a sensitivity and specificity of 95%, which is substantially equivalent to the performance of amyloid PET imaging and CSF testing [8]. - Blood draws for the test can be conducted in a physician's office or at any of Labcorp's over 2,000 Patient Service Centers (PSCs) nationwide, making it more accessible [8]. Group 2: Market Context and Impact - An estimated 6.9 million Americans are currently living with Alzheimer's disease, a figure projected to nearly double by 2050, highlighting the growing need for effective diagnostic tools [3]. - The average time from the onset of symptoms to diagnosis is approximately 2.8 years, indicating a significant delay in the current diagnostic process [3]. - The introduction of this test aims to reduce the time and anxiety associated with diagnosing Alzheimer's disease, enabling more timely and informed treatment decisions for patients and their families [4]. Group 3: Company Overview - Labcorp is a global leader in laboratory services, providing insights and advancing science to improve health through diagnostics and drug development capabilities [7]. - The company employs nearly 70,000 individuals and serves clients in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [7].